Shopping Cart
- Remove All
- Your shopping cart is currently empty
Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $448 | In Stock | |
5 mg | $1,170 | In Stock | |
10 mg | $1,870 | In Stock |
Description | Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies. |
In vivo | Atacicept (100 μg; intraperitoneal injection; three times per week for 14 days) significantly reduced the number of mature B cells and serum antibody levels in BALB/c mice. Atacicept (100 μg; intraperitoneal injection; three times per week for 21 days) effectively inhibited disease progression and autoantibody titers in a mouse model of collagen-induced arthritis (CIA).[1] |
Alias | VT-001, VT001 |
Cas No. | 845264-92-8 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.